Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Trinity Biotech

Trinity Biotech develops, manufactures and markets diagnostic test kits for the clinical laboratory and point-of-care... read more Featured Products: More products

Download Mobile App




Rapid Syphilis Test Evaluated as Tool for Public Health Programs

By LabMedica International staff writers
Posted on 09 Nov 2016
A rapid commercial treponemal syphilis-screening test is a new tool for public health programs to combat increasing syphilis rates, specifically among persons without a prior syphilis infection.

The Syphilis Health Check (SHC) test can be performed by non-laboratorian healthcare personnel and results are available in 10 minutes and have recently received a Clinical Laboratory Improvement Amendments waiver.

Scientists at the Florida Department of Health (Tampa, FL, USA) in collaboration with The Centers of Disease Control and Prevention (CDC, Atlanta, GA, USA) evaluated the performance of SHC in comparison with treponemal and nontreponemal tests routinely used in its sexually transmitted disease (STD) clinic. More...
For this evaluation, patients seeking sexually transmitted diseases (STD) testing at the Florida Department of Health STD clinic in Escambia County during March 11 to April 21, 2016, were tested for syphilis using the SHC on blood specimens obtained by fingerstick; a venous blood specimen was drawn concurrently and submitted for treponemal and testing at the state public health laboratory.

Trep-Sure qualitative enzyme immunoassay (EIA) reference treponemal test was used as the standard for “true” positive or negative treponemal test results, when evaluating the SHC. The rapid plasma reagin (RPR) card for syphilis was also tested. The SHC was used to screen 202 patients for syphilis. Among these patients, 171 (85%) were nonreactive on all syphilis tests (SHC, EIA, and RPR), 26 (13%) had a reactive SHC, and five (2%) had a nonreactive SHC, but had one or more reactive tests at the state laboratory.

Among the 26 reactive SHCs, 10 (38%) had a reactive EIA (six had a reactive RPR), and 16 (62%) were not confirmed by EIA or RPR at the state laboratory. For the six reactive SHC patients with reactive EIA and reactive RPR, three were staged as secondary syphilis, one as primary syphilis, one as early latent syphilis, and one was a previously treated positive with no increase in titer since last testing. Among the five specimens that were reactive on other tests but SHC nonreactive, only one was both RPR (1:8 serum dilution) and EIA reactive. The sensitivity of SHC was 71.4% when compared with the Trep-Sure (EIA) reference treponemal test. The specificity of the SHC compared with the reference treponemal test was 91.5%. The study was published on October 28, 2016, in the journal Morbidity and Mortality Weekly Report.

Related Links:
Florida Department of Health
The Centers of Disease Control and Prevention

New
Gold Member
Collection and Transport System
PurSafe Plus®
Collection and Transport System
PurSafe Plus®
New
Human Estradiol Assay
Human Estradiol CLIA Kit
New
Gold Member
Cardiovascular Risk Test
Metabolic Syndrome Array I & II
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Hematology

view channel
Image: New research points to protecting blood during radiation therapy (Photo courtesy of 123RF)

Pioneering Model Measures Radiation Exposure in Blood for Precise Cancer Treatments

Scientists have long focused on protecting organs near tumors during radiotherapy, but blood — a vital, circulating tissue — has largely been excluded from dose calculations. Each blood cell passing through... Read more

Immunology

view channel
Image: The VENTANA HER2 (4B5) test is now CE-IVDR approved (Photo courtesy of Roche)

Companion Diagnostic Test Identifies HER2-Ultralow Breast Cancer and Biliary Tract Cancer Patients

Breast cancer is the most common cancer in Europe, with more than 564,000 new cases and 145,000 deaths annually. Metastatic breast cancer is rising in younger populations and remains the leading cause... Read more

Pathology

view channel
Image: An adult fibrosarcoma case report has shown the importance of early diagnosis and targeted therapy (Photo courtesy of Sultana and Sailaja/Oncoscience)

Accurate Pathological Analysis Improves Treatment Outcomes for Adult Fibrosarcoma

Adult fibrosarcoma is a rare and highly aggressive malignancy that develops in connective tissue and often affects the limbs, trunk, or head and neck region. Diagnosis is complex because tumors can mimic... Read more

Technology

view channel
Image: Conceptual design of the CORAL capsule for microbial sampling in the small intestine (H. Mohammed et al., Device (2025). DOI: 10.1016/j.device.2025.100904)

Coral-Inspired Capsule Samples Hidden Bacteria from Small Intestine

The gut microbiome has been linked to conditions ranging from immune disorders to mental health, yet conventional stool tests often fail to capture bacterial populations in the small intestine.... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.